Physician and patient preferences for sustained release antihypertensive preparations in the Kumasi metropolis, Ghana
Main Article Content
Abstract
Background: Non-adherence to therapy is a major reason for the low control rate of hypertension in Ghana today. Sustained release (SR) antihypertensive preparations are useful in promoting adherence to therapy because of the reduced daily dosing frequency, stable drug levels and reduced toxicity which enhances compliance. One major concern about SR antihypertensives is whether they can be substituted with one another to produce the same effect.
Objectives: This study sought to determine the preferences of physicians and patients for various SR antihypertensive medications in the Kumasi metropolis of Ghana. The views of the respondents on whether the brands of the most used SR antihypertensive were therapeutically equivalent and interchangeable were ascertained.
Methods: Seventy-three (73) community pharmacies, 66 doctors and 150 patients in 50 public, private and mission hospitals and clinics within the Kumasi metropolis were purposively sampled. Respondents were interviewed via interviewer administered structured questionnaires and the information gathered was coded, entered into SPSS software version (16) and analysed. The results were presented as frequencies and proportions, and in tables as well as in figures.
Results: SR nifedipine was the most stocked and used SR antihypertensive drug while Nifecard XL (30 mg) was the preferred brand of patients and doctors. Clinicians considered effectiveness and compliance as two major reasons for their preference for SR nifedipine while patients considered affordability and availability. Sixty percent of prescribers and 41% of patients were of the opinion that all brands of SR nifedipine were interchangeable.
Conclusion: There is a gap between prescribers and patients about SR nifedipine brands interchangeability which needs to be bridged to optimize their use to attain better treatment outcomes in Ghana. There is need for continuous education on concepts of therapeutic equivalence and generics substitution for all stakeholders to address the problem of non-adherence to hypertension therapy in Ghana.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Cappuccio FP, Micah FB, Emmett L, Kerry SM, Antwi S, Martin-Peprah R, Phillips RO, Plange-Rhule J and Eastwood JB (2004). Prevalence, detection, management, and control of hypertension in Ashanti, West Africa. Hypertension 43(5): 1017-22.
Amoah AGB (2003). Hypertension in Ghana: a crosssectional community prevalence study in Greater Accra. Ethnicity and Diseases 13 (3): 310-5.
Buabeng KO, Matowe L and Plange-Rhule J (2004). Unaffordable drug prices: the major cause of noncompliance with hypertension medication in Ghana. Journal of Pharmacy and Pharmaceutical Sciences 7 (3): 350-2.
Håkonsen H and Toverud EL (2011). Special challenges for drug adherence following generic substitution in Pakistani immigrants living in
Norway. European Journal of Clinical Pharmacology 67 (2): 193-201.
Gohil MAR, Avachat AM, Soni MRS and Deshpande MTM (2013). Sustained release technology- a review. International Journal of Universal Pharmacy and Bio Sciences, 2 (4): 185-8.
Drug Interchangeability Update Information for Pharmacists (2011). 3(1) FYI Newsletter 5016-FYI, V6J 5C6: 1- 4.
Ghana National Drug Policy (2004). Policy statement, 2nd edition, p. 20.
Paveliu MS, Bengea S and Paveliu FS (2011). Generic substitution issues: Brand-generic substitution, Generic-generic substitution and generic substitution of narrow therapeutic index (NTI)/critical dose drugs. Maedica (Buchar) 6 (1): 52-8.
Ghana Statistical Service (2012). Population and Housing Census, 2010 summary of report of final results.
Ministry of Health, (2006). Health Sector Programme of Work 2007: Independent Review (Draft Report 2008). Ministry of Health, AccraGhana.
Hellerstein JK (1998). The Importance of the Physician in the Generic versus Trade-name Prescription Decision. Journal of Economics 29
(1): 108-36.
Alday RB, Gamboa MAT and Buensalida VR (2013). E-Generics: A Mobile Application. International Journal of Innovative Technology and Exploring engineering 3 (3): 2278-3075.
Harries TH, Twumasi-Abosi V, Plange-Rhule J and Cappuccio FP (2005). Hypertension management in Kumasi: barriers and prejudice? Journal of Human Hypertension 19: 975-7.
Himmel W, Simmenroth-Nayda A, Niebling W, Ledig T, Jansen RD and Kochen MM (2005). What do primary care patients think about generic drugs? International Journal of Clinical Pharmacology and Therapeutics 43 (10): 472-9.
Roman B (2009). Patients' attitudes towards generic substitution of oral atypical antipsychotics: a questionnaire-based survey in a hypothetical pharmacy setting. CNS Drugs 23 (8): 693-701.
Agyemang C, Attah-Adjepong G, Owusu-Dabo E, Aikins ADG, Addo J, Edusei AK and Ogedegbe G (2013). Stroke in Ashanti region of Ghana. Ghana Medical Journal 46 (2): 12-7.
Munger MA, Van Tassel BW and LaFleur J (2007). Medication non-adherence: an unrecognized cardiovascular risk factor. Medscape General Medicine 9: 58.
Kjønniksen I, Lindbæk M and Granås AG (2006). Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharmacy World and Science 28 (5): 284-9.